Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 2
2006 1
2007 2
2008 2
2009 1
2010 4
2011 11
2012 5
2013 13
2014 13
2015 11
2016 17
2017 15
2018 19
2019 16
2020 24
2021 41
2022 24
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31692017

191 results

Results by year

Filters applied: . Clear all
Page 1
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, Gilletta De Saint-Joseph C, Nancey S, Rahier JF, Bossuyt P, Cremer A, Dewit S, Eriksson C, Hoentjen F, Krause T, Louis E, Macken E, Milenkovic Z, Nijs J, Posen A, Van Hootegem A, Van Moerkercke W, Vermeire S, Bar-Gil Shitrit A, Ferrante M. Moens A, et al. Aliment Pharmacol Ther. 2020 Jan;51(1):129-138. doi: 10.1111/apt.15539. Epub 2019 Nov 6. Aliment Pharmacol Ther. 2020. PMID: 31692017 Free article.
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
Wils P, Seksik P, Stefanescu C, Nancey S, Allez M, Pineton de Chambrun G, Altwegg R, Gilletta C, Vuitton L, Viennot S, Serrero M, Fumery M, Savoye G, Collins M, Goutorbe F, Brixi H, Bouguen G, Tavernier N, Boualit M, Amiot A, Abitbol V, Laharie D, Pariente B; PREGNANCY-GETAID study group. Wils P, et al. Aliment Pharmacol Ther. 2021 Feb;53(4):460-470. doi: 10.1111/apt.16192. Epub 2020 Dec 7. Aliment Pharmacol Ther. 2021. PMID: 33345331
Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, van der Woude CJ; Dutch Delta IBD Group. Zelinkova Z, et al. Clin Gastroenterol Hepatol. 2013 Mar;11(3):318-21. doi: 10.1016/j.cgh.2012.10.024. Epub 2012 Oct 25. Clin Gastroenterol Hepatol. 2013. PMID: 23103819
Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease.
Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, Peyrin-Biroulet L, Marteau P, Cadiot G, Laharie D, Boureille A, De Vos M, Savoye G, Rahier JF, Carbonnel F, Bonaz B, Colombel JF, Bouhnik Y. Seirafi M, et al. Aliment Pharmacol Ther. 2014 Aug;40(4):363-73. doi: 10.1111/apt.12833. Epub 2014 Jun 30. Aliment Pharmacol Ther. 2014. PMID: 24980270 Free article.
191 results